Keros Therapeutics

Keros Therapeutics: A leader in understanding the role of the Transforming Growth Factor-Beta family of proteins that is a master regulator of red blood cell and platelet production as well as the growth, repair and maintenance of muscle and bone. Lead protein therapeutic product candidate, KER-050, an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-β receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome (MDS) and myelofibrosis. KER-012, is designed to bind to and inhibit the signaling of TGF-β ligands that suppress bone growth, including activin A and activin B and is being developed for the treatment of PAH and for the treatment of disorders associated with bone loss, such as osteogenesis imperfecta and osteoporosis.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Clinical Stage
Phase l or ll
Disease Space
Hematology, Metabolic Disorders, Oncology, Rare Disease
Listing
Public, USA
Market Cap
500MM - 1B
Website:
Profiles:
Address:
99 Hayden Avenue
Suite 120 (Building E)
Lexington, MA 02421
United States

Company Participants at Solebury 1x1 Management Access Event 2023

  • Jasbir Seehra, CEO

Top 10 Holders of Keros Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Fidelity Management & Research Co. LLC 13.62 4,028,136 128.42 13F 6/30/23
OrbiMed Advisors LLC 5.12 1,514,734 48.29 13F 6/30/23
Alkeon Capital Management LLC (13F Subfiler) 4.85 1,434,036 45.72 13F 6/30/23
T Rowe Price Associates, Inc. (13F Subfiler) 4.26 1,260,801 40.19 13F 6/30/23
Braidwell LP 3.87 1,143,865 36.47 13F 6/30/23
Vanguard Group, Inc. (Subfiler) 3.81 1,125,958 35.90 13F 6/30/23
State Street Corp. 3.43 1,015,903 32.39 13F 6/30/23
Candriam Belgium SA 3.36 970,027 30.92 Funds 5/31/23
BlackRock Fund Advisors 3.06 905,984 28.88 13F 6/30/23
T. Rowe Price Associates, Inc. (Investment Management) 2.86 845,068 26.94 Funds 6/30/23
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.